Tesamorelin: research overview

The short version

Tesamorelin is a synthetic analogue of the body's own growth hormone-releasing hormone (GHRH). It prompts the pituitary gland to release more growth hormone in its natural pulsatile rhythm, which in turn raises IGF-1 and drives preferential breakdown of visceral fat.

The key fact about tesamorelin: it is FDA-approved for one specific indication — reducing excess abdominal fat in HIV-infected adults with antiretroviral-related lipodystrophy. That is the population in which it was trialed and for which there is strong evidence. A 2026 meta-analysis of five RCTs found it reduced visceral fat by a mean of 27.71 cm² and hepatic fat fraction by 4.28% in that population, while increasing lean mass ^[17]. Everything outside that indication — general visceral-fat reduction, anti-aging, cognitive effects, non-HIV metabolic disease — is off-label and investigational.

This page reports the approved-indication evidence. It does not advise on off-label use or any dose.

What it is

Tesamorelin (also coded TH9507) is a synthetic 44-amino-acid analogue of human GHRH(1-44)-NH2 bearing a trans-3-hexenoic acid group conjugated to the N-terminus. That N-terminal modification is the key structural change: it confers resistance to cleavage by dipeptidyl peptidase-IV (DPP-IV), extending plasma stability relative to native GHRH. Empirical formula (free base): C221H366N72O67S; supplied as the acetate salt.

FDA approved it in November 2010 under NDA 022505 to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. Its pharmacological class is growth hormone-releasing hormone receptor agonist — not a GLP-1 agonist, not an incretin, not growth hormone itself. It is also a WADA-prohibited substance (S2: peptide hormones, growth factors, and mimetics), prohibited in- and out-of-competition ^[18].

How it works

Tesamorelin binds the GHRH receptor (GHRH-R) on somatotroph cells in the anterior pituitary, activating the Gs/adenylyl-cyclase/cAMP/PKA cascade. This stimulates synthesis and pulsatile secretion of endogenous growth hormone.

The GH released then:

1. Drives hepatic production of insulin-like growth factor-1 (IGF-1).
2. Together with IGF-1, promotes lipolysis — specifically visceral adipose tissue — through hormone-sensitive lipase activation in adipocytes.
3. Because it amplifies the body's own pulsatile GH rhythm rather than supplying exogenous GH at supraphysiological levels, its metabolic profile differs from recombinant GH, and in healthy-male pharmacology studies, insulin sensitivity was preserved ^[20].

In healthy men (n=13) treated for 2 weeks, tesamorelin raised mean overnight GH by +0.5 µg/L (P=0.004) and IGF-1 by 181 µg/L (P<0.0001), with no significant effect on fasting glucose or insulin-stimulated glucose uptake ^[20].

What the research shows

Meta-analysis of RCTs in HIV lipodystrophy (2026). A pooled analysis of five RCTs in HIV-associated lipodystrophy found tesamorelin reduced visceral adipose tissue (mean difference -27.71 cm², 95% CI -38.37 to -17.06; P<0.001), trunk fat (-1.18 kg), and hepatic fat fraction (-4.28%), while increasing lean body mass (+1.42 kg), all P<0.001, without serious adverse events ^[17].

Visceral fat and liver fat in HIV adults (JAMA RCT, 2014). In a 6-month RCT of 50 antiretroviral-treated HIV adults, tesamorelin 2 mg/day produced a treatment effect of -42 cm² in visceral fat (P=0.005) and reduced hepatic lipid-to-water percentage by a net -2.9% (P=0.003) ^[19].

GH axis pharmacology in healthy men (2011). In 13 healthy men over 2 weeks, tesamorelin raised overnight GH and IGF-1 markedly without affecting fasting glucose or insulin sensitivity ^[20].

52-week sustained efficacy and discontinuation (2008). In a program of 273 treated and 137 placebo participants, visceral fat reduction was sustained at -18% versus baseline over 52 weeks (P<0.001); visceral fat reaccumulated upon discontinuation; glucose changes over 52 weeks were not clinically significant ^[21].

Liver-safety profile. The NIH LiverTox monograph assigns tesamorelin a likelihood score of E — unlikely cause of clinically apparent liver injury — noting no reported attributable liver-injury cases and no de novo serum-enzyme elevations in trials ^[18].

Reported effects, cautions & safety

On real-world signals: tesamorelin's real-world evidence base is drawn almost entirely from clinical-trial populations with HIV-associated lipodystrophy. Unlike the incretin compounds on this desk, there is no substantial community self-report record for off-label use documented in this desk's source material; the safety picture below comes from the clinical-trial literature.

Safety cautions from the literature.

• Narrow approved indication: FDA approval is limited to HIV-associated lipodystrophy. All other uses — general visceral-fat reduction, anti-aging, non-HIV metabolic disease, cognitive effects — are off-label and investigational, without the evidentiary backing of large RCTs in those populations ^[18].
• Visceral fat reaccumulation on discontinuation: The 52-week program demonstrated clear reaccumulation of visceral fat after stopping; benefits are contingent on continued use ^[21].
• GH-axis stimulation and IGF-1 elevation: Trials showed no excess malignancy signal over 52 weeks, but long-term oncologic-safety data are limited. Active malignancy is a labeled contraindication ^[18].
• Glucose perturbation: Modest glucose changes can occur; monitoring is warranted in individuals with prediabetes or dysglycemia, though the dedicated type-2-diabetes study found no significant HbA1c change ^[21].
• WADA prohibition: Tesamorelin is prohibited in sport under S2 (peptide hormones, growth factors, related substances and mimetics) in- and out-of-competition ^[18].
• Research-grade material: Research-grade tesamorelin lacks the purity and potency oversight of the FDA-approved product ^[18].
• Generalizability: Pivotal trials were conducted in HIV-positive adults on antiretroviral therapy; the effect in non-HIV populations is mechanistically plausible but not established by large RCTs ^[17].

Where it fits

Tesamorelin is the outlier on this desk in an instructive way. The three incretin compounds (semaglutide, tirzepatide, retatrutide) all converge on energy homeostasis through the gut-hormone-to-brain-to-pancreas axis. Tesamorelin approaches the same metabolic territory — specifically visceral fat — through a completely different mechanism: the pituitary-GH-IGF-1 axis. That distinction makes it useful as a contrast: different leverage point, different population, different regulatory status, different evidence base.

Its approved indication is specific and narrow. Its off-label potential is frequently discussed; the evidence for it in non-HIV populations is thin. The desk presents it as what it is: an approved drug for one condition, with plausible but investigational extensions. See the comparison page for how its mechanism and evidence level line up against the incretin compounds.